Article in JCO precision oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 2 institutions in 2 countries.
Zehra OrduluDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL.ORCID 0000-0002-3218-1075
Peter GiuntaCenter for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.ORCID 0009-0002-8906-431X
Wei-Ting HungCenter for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
Yin P HungDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.ORCID 0000-0002-8568-1591
Judit SimonDepartment of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
Florian J FintelmannDepartment of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital and Harvard Medical School, Boston, MA.ORCID 0000-0002-0119-3903
Jochen K LennerzDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.ORCID 0000-0003-2434-4978
Kamila NaxerovaCenter for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
Gregory M CoteDepartment of Internal Medicine, Division of Hematology/Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.ORCID 0000-0003-0181-886X
Harvard University · USUniversity of Florida · US
Funding
Illuminating the evolutionary history of colorectal cancer metastasis: basic principles and clinical applicationsR37CA225655 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI NAXEROVA, KAMILA · 2018 to 2024
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Sensitivity to ALK-Directed Therapy in Osteosarcoma With an Acquired · full record | OpenQuestion